Drug Search Results
More Filters [+]

ICA-105665

Alternative Names: ica-105665, ica105665, ica 105665
Latest Update: 2012-10-04
Latest Update Note: Clinical Trial Update

Product Description

a Kv7 channel opener; Mechanistic studies showed PF-04895162 had low cytotoxic potential in human hepatocytes, but inhibited liver mitochondrial function and bile salt export protein (BSEP) transport. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/30784208/)

Mechanisms of Action: Potassium Channel Agonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for ICA-105665

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Epilepsy

Phase 1: Hyperalgesia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ICA-105665-04

P2

Terminated

Epilepsy

2010-09-01

ICA-105665-05

P1

Completed

Hyperalgesia

2009-12-01

Recent News Events

Date

Type

Title